Melissa Toyos, MD
Ophthalmology · Memphis, TNNPI 1245223502
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $974,748 of the $1,260,620 with a category attached, or 77.3%. 33 manufacturers reported payments, led by Mallinckrodt Hospital Products Inc. at 49.8% of the total. Among ophthalmology clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,269 payments — averaging $993.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Hospital Products Inc.$628K
- Sun Pharmaceutical Industries Inc.$217K
- Bausch & Lomb Americas Inc.$158K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$112K
- Mallinckrodt Enterprises LLC$73K
- Recordati_rare_diseases_inc.$35K
- plus $38K from 27 others
Across 89 payments — averaging $9541.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Dompe Farmaceutici S.p.a.$199K
- Mallinckrodt Hospital Products Inc.$157K
- Dompe US, Inc.$148K
- Bausch Health US, LLC$133K
- Novartis$119K
- Bausch & Lomb Americas Inc.$28K
- plus $65K from 6 others
What the payments were for
- Consulting fees$119,1739%
- Speaking & faculty fees$974,74877%
- Travel & lodging$128,17110%
- Food & beverage$31,8533%
- Education$6,5961%
- Gifts$790%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Hospital Products Inc. | 459 | $627,564 |
| Sun Pharmaceutical Industries Inc. | 257 | $217,143 |
| Bausch & Lomb Americas Inc. | 165 | $157,654 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 149 | $112,386 |
| Mallinckrodt Enterprises LLC | 67 | $72,621 |
| Recordati_rare_diseases_inc. | 9 | $35,035 |
| Dompe US, Inc. | 50 | $30,775 |
| Carl Zeiss Meditec, Inc. | 9 | $1,453 |
| Alcon | 28 | $1,283 |
| Oyster Point Pharma, Inc. | 10 | $700 |
| Lumibird Medical Inc. | 5 | $559 |
| Novartis | 5 | $510 |
| Quidel Corporation | 2 | $474 |
| Eyevance Pharmaceuticals LLC | 9 | $457 |
| Carl Zeiss Meditec USA, Inc. | 3 | $374 |
| Kala Pharmaceuticals, Inc. | 7 | $264 |
| ANI Pharmaceuticals, Inc. | 5 | $211 |
| Shire North American Group Inc | 4 | $158 |
| AbbVie(2 entities) | 5 | $128 |
| Omeros Corporation | 1 | $125 |
| Lumenis BE Inc | 1 | $124 |
| Harrow Eye, LLC | 2 | $84 |
| Medtronic | 2 | $75 |
| Lumenis, Inc | 2 | $66 |
| Amgen(2 entities) | 3 | $64 |
| Biohaven Pharmaceuticals, Inc. | 1 | $59 |
| Iridex Corporation | 1 | $57 |
| Rxsight Inc | 1 | $56 |
| Heidelberg Engineering, Inc. | 2 | $50 |
| Carl Zeiss Meditec AG | 2 | $39 |
| Glaukos Corporation | 1 | $33 |
| Thea Pharma Inc. | 1 | $24 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACTHAR$691,485
- CEQUA$186,220
- MIEBO$96,647
- LOTEMAX SM$52,022
- XIIDRA$45,398
- PROLENSA$43,570
- BROMSITE$26,869
- BESIVANCE$10,356
- LOTEMAX$4,422
- Oxervate$1,685
- Eye Health$797
- CALLISTO eye$500
- OPMI Lumera 700$500
- IOLMaster 700$500
- TYRVAYA$387
- VisuMax$354
- TANGO OPTIMO$347
- Flarex$334
- Clareon$268
- VYZULTA$261
How this compares
$1,260,621 in reported general payments places this provider in the 95th percentile of 323 ophthalmology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 21 | $1,112,464 |
| CequaCyclosporine | 15 | $11,974 |
| LumiganBimatoprost | 11 | $3,037 |
| Latanoprost | 66 | $566 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 14 | $222 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $30,775 | $1,112,46421 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $217,143 | $11,97415 claims |
| AbbVieLumigan | $128 | $3,03711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 323 ophthalmology providers in Tennessee.
Other ophthalmology in Memphis
- Rolando ToyosMemphis$809K
- Brian FowlerMemphis$206K
- Brian JerkinsMemphis$150K
- James FreemanMemphis$141K
- John FreemanMemphis$136K
- Penny AsbellMemphis$131K
- Kourtney HouserMemphis$104K
- Subba GollamudiMemphis$67K
- Andrew CrothersMemphis$13K
- Brian SmithMemphis$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.